Table 1 Patient characteristics
Variable | No. (%) or Median (Range) |
|---|---|
Age, years | 68 (50–85) |
Race and ethnicity | |
African-American | 3 (1.6%) |
Asian | 4 (2.1%) |
Hispanic | 2 (1.0%) |
White | 176 (91.7%) |
Unknown | 7 (3.6%) |
T stage | |
T1 | 104 (54.2%) |
T2a | 49 (25.5%) |
T2b | 25 (13.0%) |
T2c | 4 (2.1%) |
T3-T4 | 10 (5.2%) |
PSA, ng/ml | 7.2 (1.6–69.6) |
Gleason score | |
6 | 42 (21.9%) |
7 = 3 + 4 | 80 (41.7%) |
7 = 4 + 3 | 36 (18.8%) |
8 | 14 (7.3%) |
9–10 | 20 (10.4%) |
Risk category | |
Low | 38 (19.8%) |
Intermediate | 104 (54.2%) |
High | 50 (26.0%) |
Baseline IPSS Bother scorea | 2 (0–7) |
Baseline IPSS scorea | 6 (0–28) |
Baseline EPIC bowel domain scorea | 96 (61–100) |
Baseline SHIM scoreab | 18 (0–25) |
Comorbidities | |
History of diabetes | 19 (9.9%) |
History of hypertension | 96 (50.0%) |
History of inflammatory bowel disease | 2 (1.0) |
History of hemorrhoids | 26 (13.5%) |
Smoking statusa | |
Never | 103 (57.5%) |
Former | 65 (36.3%) |
Current | 11 (6.1%) |
Aspirin use | 74 (38.5%) |
Anticoagulant use | 22 (11.5%) |
Pre-treatment urologic function | |
Alpha blocker use | 37 (19.3%) |
Alpha reductase inhibitor use | 14 (7.3%) |
TURP | 9 (4.7%) |
Androgen deprivation therapy | 71 (37.0%) |
Low risk | 1/71 (1.4%) |
Intermediate risk | 27/71 (38.0%) |
High risk | 43/71 (60.6%) |
Pencil beam vs. uniform scanning | 144 vs 48 (75.0% vs 25%) |
Number of fields/day | |
1 | 92 (48%) |
2 | 100 (52%) |
Whole pelvis radiation | 19 (9.9%) |
US-based prostate volume, cm3 | 40 (12–100) |